However, the risk of secondary myelodysplastic syndrome and AML in cancer patients treated with PARP inhibitors such as olaparib and veliparib63 raises concerns about their use in myeloid leukemia and hematological malignancies more broadly. This evidence concerns the gene PARP1 and myeloid leukemia.